b16f10 Search Results


99
ATCC murine melanoma cell line b16f10
Murine Melanoma Cell Line B16f10, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/murine melanoma cell line b16f10/product/ATCC
Average 99 stars, based on 1 article reviews
murine melanoma cell line b16f10 - by Bioz Stars, 2026-02
99/100 stars
  Buy from Supplier

92
Revvity bw124734

Bw124734, supplied by Revvity, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bw124734/product/Revvity
Average 92 stars, based on 1 article reviews
bw124734 - by Bioz Stars, 2026-02
92/100 stars
  Buy from Supplier

95
ATCC b16f10luc2 cells

B16f10luc2 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/b16f10luc2 cells/product/ATCC
Average 95 stars, based on 1 article reviews
b16f10luc2 cells - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier

94
CLS Cell Lines Service GmbH cell culture murine melanoma b16 f10 cells

Cell Culture Murine Melanoma B16 F10 Cells, supplied by CLS Cell Lines Service GmbH, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cell culture murine melanoma b16 f10 cells/product/CLS Cell Lines Service GmbH
Average 94 stars, based on 1 article reviews
cell culture murine melanoma b16 f10 cells - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

96
AMS Biotechnology b16 f10 cells
(A1) <t>B16.F10</t> cells and (A2) RM11 cells treated or not treated (control) with biotinylated anti-CD29 antibodies (anti-CD29-biotin) followed by strepavidin-PE. (B–F) Validation of cell-particle hybrid assembly from B16.F10 or RM11 cells subsequent to surface biotinylation using anti-CD29-biotin and mixed with streptavidin-coated particles loaded with rhodamine B and washed to remove unbound particles (hybrid). Control involved the same conditions except cells were not treated with anti-CD29-biotin. Validation was performed using: (B1–2 and E1–2): flow cytometry where (B1 and E1) representive (n = 1) and (B2 and E2) mean (n = 3) results from measuring relative mean rhodamine fluorescence intensity (RMFI(Rh)) of (B1 and B2) B16.F10 and (E1 and E2) RM11 cells; (C1–2 and F1–2): laser scanning confocal microscopy showing (C1 and F1) hybrid and (C2 and F2) control cell-particle mixtures for (C1 and C2) B16.F10 and (F1 and F2) RM11 cells (blue = DAPI stained cell nuclei, red = rhodamine-labeled PLGA particles); (D): scanning electron microscopy showing (D1) B16.F10 hybrid and (D2) control cell-particle mixtures (arrows in C1, D1, and F1 indicate particles bound to cell surface). Scale bar= 20 micron for C1–2 and F1–2, 10 microns for D1–2. When applicable, error bars = SD. ** p < 0.01, *** p < 0.001, n = 3.
B16 F10 Cells, supplied by AMS Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/b16 f10 cells/product/AMS Biotechnology
Average 96 stars, based on 1 article reviews
b16 f10 cells - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier

91
Innovative Research Inc b16 f10 cells
(A1) <t>B16.F10</t> cells and (A2) RM11 cells treated or not treated (control) with biotinylated anti-CD29 antibodies (anti-CD29-biotin) followed by strepavidin-PE. (B–F) Validation of cell-particle hybrid assembly from B16.F10 or RM11 cells subsequent to surface biotinylation using anti-CD29-biotin and mixed with streptavidin-coated particles loaded with rhodamine B and washed to remove unbound particles (hybrid). Control involved the same conditions except cells were not treated with anti-CD29-biotin. Validation was performed using: (B1–2 and E1–2): flow cytometry where (B1 and E1) representive (n = 1) and (B2 and E2) mean (n = 3) results from measuring relative mean rhodamine fluorescence intensity (RMFI(Rh)) of (B1 and B2) B16.F10 and (E1 and E2) RM11 cells; (C1–2 and F1–2): laser scanning confocal microscopy showing (C1 and F1) hybrid and (C2 and F2) control cell-particle mixtures for (C1 and C2) B16.F10 and (F1 and F2) RM11 cells (blue = DAPI stained cell nuclei, red = rhodamine-labeled PLGA particles); (D): scanning electron microscopy showing (D1) B16.F10 hybrid and (D2) control cell-particle mixtures (arrows in C1, D1, and F1 indicate particles bound to cell surface). Scale bar= 20 micron for C1–2 and F1–2, 10 microns for D1–2. When applicable, error bars = SD. ** p < 0.01, *** p < 0.001, n = 3.
B16 F10 Cells, supplied by Innovative Research Inc, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/b16 f10 cells/product/Innovative Research Inc
Average 91 stars, based on 1 article reviews
b16 f10 cells - by Bioz Stars, 2026-02
91/100 stars
  Buy from Supplier

93
Exosome Diagnostics b16 f10
(A1) <t>B16.F10</t> cells and (A2) RM11 cells treated or not treated (control) with biotinylated anti-CD29 antibodies (anti-CD29-biotin) followed by strepavidin-PE. (B–F) Validation of cell-particle hybrid assembly from B16.F10 or RM11 cells subsequent to surface biotinylation using anti-CD29-biotin and mixed with streptavidin-coated particles loaded with rhodamine B and washed to remove unbound particles (hybrid). Control involved the same conditions except cells were not treated with anti-CD29-biotin. Validation was performed using: (B1–2 and E1–2): flow cytometry where (B1 and E1) representive (n = 1) and (B2 and E2) mean (n = 3) results from measuring relative mean rhodamine fluorescence intensity (RMFI(Rh)) of (B1 and B2) B16.F10 and (E1 and E2) RM11 cells; (C1–2 and F1–2): laser scanning confocal microscopy showing (C1 and F1) hybrid and (C2 and F2) control cell-particle mixtures for (C1 and C2) B16.F10 and (F1 and F2) RM11 cells (blue = DAPI stained cell nuclei, red = rhodamine-labeled PLGA particles); (D): scanning electron microscopy showing (D1) B16.F10 hybrid and (D2) control cell-particle mixtures (arrows in C1, D1, and F1 indicate particles bound to cell surface). Scale bar= 20 micron for C1–2 and F1–2, 10 microns for D1–2. When applicable, error bars = SD. ** p < 0.01, *** p < 0.001, n = 3.
B16 F10, supplied by Exosome Diagnostics, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/b16 f10/product/Exosome Diagnostics
Average 93 stars, based on 1 article reviews
b16 f10 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

90
Korean Cell Line Bank b16f10 human melanoma carcinoma cells
(A1) <t>B16.F10</t> cells and (A2) RM11 cells treated or not treated (control) with biotinylated anti-CD29 antibodies (anti-CD29-biotin) followed by strepavidin-PE. (B–F) Validation of cell-particle hybrid assembly from B16.F10 or RM11 cells subsequent to surface biotinylation using anti-CD29-biotin and mixed with streptavidin-coated particles loaded with rhodamine B and washed to remove unbound particles (hybrid). Control involved the same conditions except cells were not treated with anti-CD29-biotin. Validation was performed using: (B1–2 and E1–2): flow cytometry where (B1 and E1) representive (n = 1) and (B2 and E2) mean (n = 3) results from measuring relative mean rhodamine fluorescence intensity (RMFI(Rh)) of (B1 and B2) B16.F10 and (E1 and E2) RM11 cells; (C1–2 and F1–2): laser scanning confocal microscopy showing (C1 and F1) hybrid and (C2 and F2) control cell-particle mixtures for (C1 and C2) B16.F10 and (F1 and F2) RM11 cells (blue = DAPI stained cell nuclei, red = rhodamine-labeled PLGA particles); (D): scanning electron microscopy showing (D1) B16.F10 hybrid and (D2) control cell-particle mixtures (arrows in C1, D1, and F1 indicate particles bound to cell surface). Scale bar= 20 micron for C1–2 and F1–2, 10 microns for D1–2. When applicable, error bars = SD. ** p < 0.01, *** p < 0.001, n = 3.
B16f10 Human Melanoma Carcinoma Cells, supplied by Korean Cell Line Bank, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/b16f10 human melanoma carcinoma cells/product/Korean Cell Line Bank
Average 90 stars, based on 1 article reviews
b16f10 human melanoma carcinoma cells - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
COLD SPRING BIOTECH CORP firefly luciferase-expressing b16f10 melanoma cells
(A1) <t>B16.F10</t> cells and (A2) RM11 cells treated or not treated (control) with biotinylated anti-CD29 antibodies (anti-CD29-biotin) followed by strepavidin-PE. (B–F) Validation of cell-particle hybrid assembly from B16.F10 or RM11 cells subsequent to surface biotinylation using anti-CD29-biotin and mixed with streptavidin-coated particles loaded with rhodamine B and washed to remove unbound particles (hybrid). Control involved the same conditions except cells were not treated with anti-CD29-biotin. Validation was performed using: (B1–2 and E1–2): flow cytometry where (B1 and E1) representive (n = 1) and (B2 and E2) mean (n = 3) results from measuring relative mean rhodamine fluorescence intensity (RMFI(Rh)) of (B1 and B2) B16.F10 and (E1 and E2) RM11 cells; (C1–2 and F1–2): laser scanning confocal microscopy showing (C1 and F1) hybrid and (C2 and F2) control cell-particle mixtures for (C1 and C2) B16.F10 and (F1 and F2) RM11 cells (blue = DAPI stained cell nuclei, red = rhodamine-labeled PLGA particles); (D): scanning electron microscopy showing (D1) B16.F10 hybrid and (D2) control cell-particle mixtures (arrows in C1, D1, and F1 indicate particles bound to cell surface). Scale bar= 20 micron for C1–2 and F1–2, 10 microns for D1–2. When applicable, error bars = SD. ** p < 0.01, *** p < 0.001, n = 3.
Firefly Luciferase Expressing B16f10 Melanoma Cells, supplied by COLD SPRING BIOTECH CORP, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/firefly luciferase-expressing b16f10 melanoma cells/product/COLD SPRING BIOTECH CORP
Average 90 stars, based on 1 article reviews
firefly luciferase-expressing b16f10 melanoma cells - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
BioResource International Inc b16f10 murine melanoma cells
Characterization of EGCG-pNG versus cell viabilities after 24 hours of treatment
B16f10 Murine Melanoma Cells, supplied by BioResource International Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/b16f10 murine melanoma cells/product/BioResource International Inc
Average 90 stars, based on 1 article reviews
b16f10 murine melanoma cells - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
Jackson Laboratory b16-f10 cells
Characterization of EGCG-pNG versus cell viabilities after 24 hours of treatment
B16 F10 Cells, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/b16-f10 cells/product/Jackson Laboratory
Average 90 stars, based on 1 article reviews
b16-f10 cells - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
Amorepacific Corporation b16f10
Characterization of EGCG-pNG versus cell viabilities after 24 hours of treatment
B16f10, supplied by Amorepacific Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/b16f10/product/Amorepacific Corporation
Average 90 stars, based on 1 article reviews
b16f10 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


Journal: Cell reports

Article Title: Chronic stress physically spares but functionally impairs innate-like invariant T cells

doi: 10.1016/j.celrep.2021.108979

Figure Lengend Snippet:

Article Snippet: Mouse: B16-F10-Red-FLuc (B16-FLuc) melanoma cells , PerkinElmer , Cat # BW124734.

Techniques: Control, Recombinant, Western Blot, Enzyme-linked Immunosorbent Assay, Staining, In Situ, Selection, cDNA Synthesis, Software

(A1) B16.F10 cells and (A2) RM11 cells treated or not treated (control) with biotinylated anti-CD29 antibodies (anti-CD29-biotin) followed by strepavidin-PE. (B–F) Validation of cell-particle hybrid assembly from B16.F10 or RM11 cells subsequent to surface biotinylation using anti-CD29-biotin and mixed with streptavidin-coated particles loaded with rhodamine B and washed to remove unbound particles (hybrid). Control involved the same conditions except cells were not treated with anti-CD29-biotin. Validation was performed using: (B1–2 and E1–2): flow cytometry where (B1 and E1) representive (n = 1) and (B2 and E2) mean (n = 3) results from measuring relative mean rhodamine fluorescence intensity (RMFI(Rh)) of (B1 and B2) B16.F10 and (E1 and E2) RM11 cells; (C1–2 and F1–2): laser scanning confocal microscopy showing (C1 and F1) hybrid and (C2 and F2) control cell-particle mixtures for (C1 and C2) B16.F10 and (F1 and F2) RM11 cells (blue = DAPI stained cell nuclei, red = rhodamine-labeled PLGA particles); (D): scanning electron microscopy showing (D1) B16.F10 hybrid and (D2) control cell-particle mixtures (arrows in C1, D1, and F1 indicate particles bound to cell surface). Scale bar= 20 micron for C1–2 and F1–2, 10 microns for D1–2. When applicable, error bars = SD. ** p < 0.01, *** p < 0.001, n = 3.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Article Title: Surface Engineering Tumor Cells with Adjuvant-loaded Particles for Use as Cancer Vaccines

doi: 10.1016/j.jconrel.2016.12.036

Figure Lengend Snippet: (A1) B16.F10 cells and (A2) RM11 cells treated or not treated (control) with biotinylated anti-CD29 antibodies (anti-CD29-biotin) followed by strepavidin-PE. (B–F) Validation of cell-particle hybrid assembly from B16.F10 or RM11 cells subsequent to surface biotinylation using anti-CD29-biotin and mixed with streptavidin-coated particles loaded with rhodamine B and washed to remove unbound particles (hybrid). Control involved the same conditions except cells were not treated with anti-CD29-biotin. Validation was performed using: (B1–2 and E1–2): flow cytometry where (B1 and E1) representive (n = 1) and (B2 and E2) mean (n = 3) results from measuring relative mean rhodamine fluorescence intensity (RMFI(Rh)) of (B1 and B2) B16.F10 and (E1 and E2) RM11 cells; (C1–2 and F1–2): laser scanning confocal microscopy showing (C1 and F1) hybrid and (C2 and F2) control cell-particle mixtures for (C1 and C2) B16.F10 and (F1 and F2) RM11 cells (blue = DAPI stained cell nuclei, red = rhodamine-labeled PLGA particles); (D): scanning electron microscopy showing (D1) B16.F10 hybrid and (D2) control cell-particle mixtures (arrows in C1, D1, and F1 indicate particles bound to cell surface). Scale bar= 20 micron for C1–2 and F1–2, 10 microns for D1–2. When applicable, error bars = SD. ** p < 0.01, *** p < 0.001, n = 3.

Article Snippet: For vaccinations, a B16.F10 GM-CSF clone expressing 220 ng GM-CSF/10 6 cells/day was derived by transducing B16.F10 cells with a lentiviral vector encoding murine GM-CSF (AMSBIO, Cambridge, MA).

Techniques: Flow Cytometry, Fluorescence, Confocal Microscopy, Staining, Labeling, Electron Microscopy

Laser scanning confocal microscopy imaging of cell-particle hybrid uptake by BMDC. Cell-particle hybrids were incubated with BMDC Yellow arrows indicating colocalization of B16.F10 cells (green) and particles (red) inside BMDC (magenta). Magenta: Alexa flour®700 (CD11c) stained BMDC, green: CFSE labeled B16.F10 melanoma cells, red: rhodamine B-labeled PLGA particles, gray: DAPI stained cell nuclei. Scale bar: 20 micron.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Article Title: Surface Engineering Tumor Cells with Adjuvant-loaded Particles for Use as Cancer Vaccines

doi: 10.1016/j.jconrel.2016.12.036

Figure Lengend Snippet: Laser scanning confocal microscopy imaging of cell-particle hybrid uptake by BMDC. Cell-particle hybrids were incubated with BMDC Yellow arrows indicating colocalization of B16.F10 cells (green) and particles (red) inside BMDC (magenta). Magenta: Alexa flour®700 (CD11c) stained BMDC, green: CFSE labeled B16.F10 melanoma cells, red: rhodamine B-labeled PLGA particles, gray: DAPI stained cell nuclei. Scale bar: 20 micron.

Article Snippet: For vaccinations, a B16.F10 GM-CSF clone expressing 220 ng GM-CSF/10 6 cells/day was derived by transducing B16.F10 cells with a lentiviral vector encoding murine GM-CSF (AMSBIO, Cambridge, MA).

Techniques: Confocal Microscopy, Imaging, Incubation, Staining, Labeling

Characterization of EGCG-pNG versus cell viabilities after 24 hours of treatment

Journal: Drug Design, Development and Therapy

Article Title: Improving anticancer efficacy of (–)-epigallocatechin-3-gallate gold nanoparticles in murine B16F10 melanoma cells

doi: 10.2147/DDDT.S58414

Figure Lengend Snippet: Characterization of EGCG-pNG versus cell viabilities after 24 hours of treatment

Article Snippet: B16F10 murine melanoma cells and African green monkey kidney cells (Vero cells, as control cells) were both obtained from the Bioresource Collection and Research Center (BCRC) of the Food Industrial Research and Development Institute, Hsinchu, Taiwan.

Techniques: Zeta Potential Analyzer

The effects of EGCG and pNG on Vero and B16F10 cell proliferation. Notes: ( A ) Cells were treated with or without increasing concentrations of EGCG for 24 hours; ( B ) cells were treated with or without increasing concentrations of pNG for 24 hours. Data shown are means ± standard deviations for three samples. Data containing asterisks are significantly different from the control values at ** P <0.01, *** P <0.001. Abbreviations: EGCG, (–)-epigallocatechin-3-gallate; pNG, physical nanogold.

Journal: Drug Design, Development and Therapy

Article Title: Improving anticancer efficacy of (–)-epigallocatechin-3-gallate gold nanoparticles in murine B16F10 melanoma cells

doi: 10.2147/DDDT.S58414

Figure Lengend Snippet: The effects of EGCG and pNG on Vero and B16F10 cell proliferation. Notes: ( A ) Cells were treated with or without increasing concentrations of EGCG for 24 hours; ( B ) cells were treated with or without increasing concentrations of pNG for 24 hours. Data shown are means ± standard deviations for three samples. Data containing asterisks are significantly different from the control values at ** P <0.01, *** P <0.001. Abbreviations: EGCG, (–)-epigallocatechin-3-gallate; pNG, physical nanogold.

Article Snippet: B16F10 murine melanoma cells and African green monkey kidney cells (Vero cells, as control cells) were both obtained from the Bioresource Collection and Research Center (BCRC) of the Food Industrial Research and Development Institute, Hsinchu, Taiwan.

Techniques: Control

Improving anti-proliferative activity of EGCG and pNG in vitro. Notes: ( A ) Morphologies of B16F10 cells treated with or without 25–50 μM EGCG and/or 1.25–2.5 ppm pNG for 24 hours (magnification ×40). Scale bar, 100 μm; ( B ) All the mixtures of EGCG and pNG underwent ultrasound pretreatment and showed significant 24-hour cytotoxicity compared with pNG or EGCG, respectively, in B16F10 but not Vero cells; ( C ) improved cytotoxicity of the EGCG and pNG mixtures was only achieved with ultrasound pretreatment; this was not observed in the mixture without ultrasound pretreatment. The cell viabilities were determined via WST-8 assay. Data shown are mean ± standard deviation for three samples. Data containing asterisks are significantly different from the control values at ** P <0.01; *** P <0.001. Abbreviations: EGCG, (–)-epigallocatechin-3-gallate; pNG, physical nanogold; E25, EGCG 25 μM; E50, EGCG 50 μM; P1.25, pNG 1.25 ppm; P2.5, pNG 2.5 ppm; E25–P1.25, EGCG-pNG 25 μM:1.25 ppm; E50–P2.5, EGCG-pNG 50 μM:2.5 ppm.

Journal: Drug Design, Development and Therapy

Article Title: Improving anticancer efficacy of (–)-epigallocatechin-3-gallate gold nanoparticles in murine B16F10 melanoma cells

doi: 10.2147/DDDT.S58414

Figure Lengend Snippet: Improving anti-proliferative activity of EGCG and pNG in vitro. Notes: ( A ) Morphologies of B16F10 cells treated with or without 25–50 μM EGCG and/or 1.25–2.5 ppm pNG for 24 hours (magnification ×40). Scale bar, 100 μm; ( B ) All the mixtures of EGCG and pNG underwent ultrasound pretreatment and showed significant 24-hour cytotoxicity compared with pNG or EGCG, respectively, in B16F10 but not Vero cells; ( C ) improved cytotoxicity of the EGCG and pNG mixtures was only achieved with ultrasound pretreatment; this was not observed in the mixture without ultrasound pretreatment. The cell viabilities were determined via WST-8 assay. Data shown are mean ± standard deviation for three samples. Data containing asterisks are significantly different from the control values at ** P <0.01; *** P <0.001. Abbreviations: EGCG, (–)-epigallocatechin-3-gallate; pNG, physical nanogold; E25, EGCG 25 μM; E50, EGCG 50 μM; P1.25, pNG 1.25 ppm; P2.5, pNG 2.5 ppm; E25–P1.25, EGCG-pNG 25 μM:1.25 ppm; E50–P2.5, EGCG-pNG 50 μM:2.5 ppm.

Article Snippet: B16F10 murine melanoma cells and African green monkey kidney cells (Vero cells, as control cells) were both obtained from the Bioresource Collection and Research Center (BCRC) of the Food Industrial Research and Development Institute, Hsinchu, Taiwan.

Techniques: Activity Assay, In Vitro, Standard Deviation, Control

Enhanced apoptosis induction of EGCG by pNG in B16F10 cells. Notes: ( A ) The fractions of annexin V-positive B16F10 cells were 3.59%±0.30%, 12.63%±0.61%, 20.93%±0.55%, and 25.7%±0.54%, after treatment with pNG 2.5 ppm, EGCG 50 μM, EGCG-pNG 50 μM:2.5 ppm, and Taxol ® (Sigma-Aldrich; St Louis, MO, USA) 0.5 μM, respectively, at 24 hours; ( B ) the fractions of annexin V-positive and PI-negative B16F10 cells were 1.0% ± 0.17%, 3.2% ± 0.23%, 6.5% ± 0.23%, and 11.7% ± 0.41%, after treatment with pNG 2.5 ppm, EGCG 50 μM, EGCG-pNG 50 μM:2.5 ppm, and Taxol ® 0.5 μM, respectively, at 24 hours; ( C ) cells treated with EGCG-pNG for 24 hours expressed more green fluorescence than those treated with EGCG (magnification ×200). Depolarized mitochondria are indicated by green fluorescence (JC-10 monomer), and polarized mitochondria are indicated by orange fluorescence (aggregated JC-10). Cell nuclei are indicated by blue fluorescence coupled with Hoechst 33342 staining. Scale bar, 10 μm; ( D ) cells treated with EGCG-pNG for 24 hours showed a significant increase of caspase-3, -8, and -9 activity compared with those treated with EGCG; ( E ) initiation of time-dependent apoptotic activation by EGCG-pNG treatment via the caspase pathway in B16F10 melanoma cells. Data shown are mean ± standard deviation for three samples. Data containing asterisks are significantly different from the control values at * P <0.05; ** P <0.01; *** P <0.001. Abbreviations: PI, propidium iodide; EGCG, (–)-epigallocatechin-3-gallate; pNG, physical nanogold; P2.5, pNG 2.5 ppm; E50, EGCG 50 μM; E50-P2.5, EGCG-pNG 50 μM:2.5 ppm; ZVAD, Z-VAD-FMK, N-Benzyloxycarbonyl-Val-Ala-Asp (O-Me) fluoromethyl ketone.

Journal: Drug Design, Development and Therapy

Article Title: Improving anticancer efficacy of (–)-epigallocatechin-3-gallate gold nanoparticles in murine B16F10 melanoma cells

doi: 10.2147/DDDT.S58414

Figure Lengend Snippet: Enhanced apoptosis induction of EGCG by pNG in B16F10 cells. Notes: ( A ) The fractions of annexin V-positive B16F10 cells were 3.59%±0.30%, 12.63%±0.61%, 20.93%±0.55%, and 25.7%±0.54%, after treatment with pNG 2.5 ppm, EGCG 50 μM, EGCG-pNG 50 μM:2.5 ppm, and Taxol ® (Sigma-Aldrich; St Louis, MO, USA) 0.5 μM, respectively, at 24 hours; ( B ) the fractions of annexin V-positive and PI-negative B16F10 cells were 1.0% ± 0.17%, 3.2% ± 0.23%, 6.5% ± 0.23%, and 11.7% ± 0.41%, after treatment with pNG 2.5 ppm, EGCG 50 μM, EGCG-pNG 50 μM:2.5 ppm, and Taxol ® 0.5 μM, respectively, at 24 hours; ( C ) cells treated with EGCG-pNG for 24 hours expressed more green fluorescence than those treated with EGCG (magnification ×200). Depolarized mitochondria are indicated by green fluorescence (JC-10 monomer), and polarized mitochondria are indicated by orange fluorescence (aggregated JC-10). Cell nuclei are indicated by blue fluorescence coupled with Hoechst 33342 staining. Scale bar, 10 μm; ( D ) cells treated with EGCG-pNG for 24 hours showed a significant increase of caspase-3, -8, and -9 activity compared with those treated with EGCG; ( E ) initiation of time-dependent apoptotic activation by EGCG-pNG treatment via the caspase pathway in B16F10 melanoma cells. Data shown are mean ± standard deviation for three samples. Data containing asterisks are significantly different from the control values at * P <0.05; ** P <0.01; *** P <0.001. Abbreviations: PI, propidium iodide; EGCG, (–)-epigallocatechin-3-gallate; pNG, physical nanogold; P2.5, pNG 2.5 ppm; E50, EGCG 50 μM; E50-P2.5, EGCG-pNG 50 μM:2.5 ppm; ZVAD, Z-VAD-FMK, N-Benzyloxycarbonyl-Val-Ala-Asp (O-Me) fluoromethyl ketone.

Article Snippet: B16F10 murine melanoma cells and African green monkey kidney cells (Vero cells, as control cells) were both obtained from the Bioresource Collection and Research Center (BCRC) of the Food Industrial Research and Development Institute, Hsinchu, Taiwan.

Techniques: Fluorescence, Staining, Activity Assay, Activation Assay, Standard Deviation, Control